The Brief

Our client is a Series B immuno-oncology biotech, spun out of the ICR and Crick Institute in 2022. Their lead programme — a TCR-engineered cell therapy for solid tumours — has cleared Phase I/Ib and is preparing to commence a 60-patient Phase IIa across UK, US, and French sites. The VP, Clinical Development will be the medical executive accountable for the programme.

Responsibilities

• 01

  Author and own the Phase IIa clinical development plan

• 02

  Lead engagement with the MHRA, FDA, and EMA

• 03

  Build a clinical operations function from 6 to 18 over 24 months

The Successful Candidate

• 01

  MD or MD/PhD with board certification in Oncology or Haematology

• 02

  Prior leadership of at least one IND or IMPD-stage programme

• 03

  Direct experience of cell or gene therapy development

Compensation & Benefits

Tags